Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9759966 | 0.74 | MAPT (0.37) | TSHRTDP1SMN1; SMN2MAPTCACNA1B | |
| SCHEMBL30543061 | 0.74 | KDM4E (0.42) | TDP1SMN1; SMN2MAPT | |
| SCHEMBL8859864 | 0.74 | KDM4E (0.42) | TDP1SMN1; SMN2MAPT | |
| SCHEMBL10975759 | 0.71 | CASP1 (0.44) | SMN1; SMN2 | |
| SCHEMBL991007 | 0.71 | ACHE (0.51) | TDP1EPHX2 | |
| SCHEMBL10976689 | 0.71 | CASP1 (0.44) | SMN1; SMN2 | |
| SCHEMBL14458906 | 0.71 | ACHE (0.51) | TDP1EPHX2 | |
| SCHEMBL2791101 | 0.70 | SMN1; SMN2 (0.52) | TSHRTDP1SMN1; SMN2MAPTCACNA1B | |
| SCHEMBL8628765 | 0.70 | SMN1; SMN2 (0.52) | TSHRTDP1SMN1; SMN2MAPTCACNA1B | |
| SCHEMBL2791099 | 0.70 | SMN1; SMN2 (0.52) | TSHRTDP1SMN1; SMN2MAPTCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777073-B2 | Topical delivery system for antiaging and skin whitening agents | BIODERM RESEARCH (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | TYR, MMP17, MMP1 | TSHR 2624/4885TDP1 1464/4885SMN1; SMN2 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.